Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

被引：76

作者：

Gerson, James N. ^{[1
]}

Handorf, Elizabeth ^{[1
]}

Villa, Diego ^{[2
]}

Gerrie, Alina S. ^{[2
]}

Chapani, Pary ^{[2
]}

Li, Shaoying ^{[3
]}

Medeiros, L. Jeffrey ^{[3
]}

Wang, Michael, I ^{[3
]}

Cohen, Jonathon B. ^{[4
]}

Calzada, Oscar ^{[4
]}

Churnetski, Michael C. ^{[4
]}

Hill, Brian T. ^{[5
]}

Sawalha, Yazeed ^{[5
]}

Hernandez-Ilizaliturri, Francisco J. ^{[6
]}

Kothari, Shalin ^{[6
]}

Vose, Julie M. ^{[7
]}

Bast, Martin A. ^{[7
]}

Fenske, Timothy S. ^{[8
]}

Gari, Swapna Narayana Rao ^{[8
]}

Maddocks, Kami J. ^{[9
]}

Bond, David ^{[9
]}

Bachanova, Veronika ^{[10
]}

Kolla, Bhaskar ^{[10
]}

Chavez, Julio ^{[11
]}

Shah, Bijal ^{[11
]}

Lansigan, Frederick ^{[12
]}

Burns, Timothy F. ^{[12
]}

Donovan, Alexandra M. ^{[12
]}

Wagner-Johnston, Nina ^{[13
]}

Messmer, Marcus ^{[13
]}

Mehta, Amitkumar ^{[14
]}

Anderson, Jennifer K. ^{[14
]}

Reddy, Nishitha ^{[15
]}

Kovach, Alexandra E. ^{[15
]}

Landsburg, Daniel J. ^{[16
]}

Glenn, Martha ^{[17
]}

Inwards, David J. ^{[18
]}

Karmali, Reem ^{[19
]}

Kaplan, Jason B. ^{[19
]}

Caimi, Paolo F. ^{[20
]}

Rajguru, Saurabh ^{[21
]}

Evens, Andrew ^{[22
]}

Klein, Andreas ^{[22
]}

Umyarova, Elvira ^{[23
]}

Pulluri, Bhargavi ^{[23
]}

Amengual, Jennifer E. ^{[24
]}

Lue, Jennifer K. ^{[24
]}

Diefenbach, Catherine ^{[25
]}

Fisher, Richard, I ^{[1
]}

Barta, Stefan K. ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] BC Canc, Vancouver, BC, Canada

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[6] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[7] Univ Nebraska, Canc Ctr, Omaha, NE 68182 USA

[8] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[9] Ohio State Univ, Columbus, OH 43210 USA

[10] Univ Minnesota, Minneapolis, MN USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[13] Johns Hopkins Univ, Baltimore, MD USA

[14] Univ Alabama Birmingham, Canc Ctr, Birmingham, AL USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA

[17] Huntsman Canc Inst, Salt Lake City, UT USA

[18] Mayo Clin, Rochester, MN USA

[19] Northwestern Univ, Evanston, IL USA

[20] Case Western Reserve Univ, Cleveland, OH 44106 USA

[21] Univ Wisconsin, Madison, WI USA

[22] Tufts Univ, Boston, MA 02111 USA

[23] Univ Vermont, Burlington, VT USA

[24] Columbia Univ, New York, NY USA

[25] NYU, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 06期

关键词：

PROGRESSION-FREE SURVIVAL; INTERNATIONAL PROGNOSTIC INDEX; RANDOMIZED-TRIALS; TRANSPLANTATION; IMMUNOCHEMOTHERAPY; PATHOGENESIS; MULTICENTER; THERAPY; PATTERN; IMPACT;

D O I：

10.1200/JCO.18.00690

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEMantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.PATIENTS AND METHODSWe retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed.RESULTSData were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2).CONCLUSIONIn this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

引用

页码：471 / +

页数：17

共 50 条

[31] Follicular Lymphoma Survival in Sweden in the Rituximab Era
Junlen, Henna Riikka
Peterson, Stefan
Kimby, Eva
Lockmer, Sandra
Linden, Ola
Nilsson-Ehle, Herman
Erlanson, Martin
Hagberg, Hans
Radlund, Anders
Hagberg, Oskar
Wahlin, Bjorn E.
BLOOD, 2014, 124 (21)
[32] Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era
Davide Bedognetti
Gabriele Zoppoli
Mario Roberto Sertoli
Elisa Zanardi
Pietro Blandini
Lorenzo Uccellini
Francesco Boccardo
Giovanni Battista Andreoli
Riccardo Ghio
Omar Racchi
Manlio Ferrarini
Andrea De Maria
International Journal of Hematology, 2010, 91 : 342 - 344
[33] Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era
Bedognetti, Davide
Zoppoli, Gabriele
Sertoli, Mario Roberto
Zanardi, Elisa
Blandini, Pietro
Uccellini, Lorenzo
Boccardo, Francesco
Andreoli, Giovanni Battista
Ghio, Riccardo
Racchi, Omar
Ferrarini, Manlio
De Maria, Andrea
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (02) : 342 - 344
[34] Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma
Tan, Jing Yuan
Qiu, Tian Yu
Chiang, Jianbang
Tan, Ya Hwee
Yang, Valerie Shiwen
Chang, Esther Wei Yin
Poon, Eileen
Somasundaram, Nagavalli
Farid, Mohamad
Tao, Miriam
Lim, Soon Thye
Chan, Jason Yongsheng
JOURNAL OF HEMATOLOGY, 2021, 10 (04) : 187 - 195
[35] Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis
Sawalha, Yazeed
Goyal, Subir
Switchenko, Jeffrey M.
Romancik, Jason T.
Kamdar, Manali
Greenwell, Irl Brian
Hess, Brian T.
Isaac, Krista
Portell, Craig A.
Garcia, Alex V. Mejia
Goldsmith, Scott R.
Grover, Natalie S.
Riedell, Peter A.
Karmali, Reem
Burkart, Madelyn
Buege, Michael J.
Akhtar, Othman S.
Torka, Pallawi
Kumar, Anita
Hill, Brian T.
Kahl, Brad S.
Cohen, Jonathon B.
BLOOD, 2020, 136
[36] OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY
Visco, C.
Di Rocco, A.
Tisi, M.
Morello, L.
Evangelista, A.
Zilioli, V. R.
Rusconi, C.
Hohaus, S.
Sciarra, R.
Re, A.
Tecchio, C.
Chiappella, A.
Niebla, A. M.
McCulloch, R.
Gini, G.
Perrone, T.
Nassi, L.
Pennese, E.
Stefani, P. M.
Cox, M. C.
Bozzoli, V.
Fabbri, A.
Polli, V.
Ferrero, S.
De Celis, I. A.
Sica, A.
Arcaini, L.
Balzarotti, M.
Rule, S.
Vitolo, U.
HAEMATOLOGICA, 2019, 104 : 7 - 7
[37] Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
Carlo Visco
Alice Di Rocco
Andrea Evangelista
Francesca Maria Quaglia
Maria Chiara Tisi
Lucia Morello
Vittorio Ruggero Zilioli
Chiara Rusconi
Stefan Hohaus
Roberta Sciarra
Alessandro Re
Cristina Tecchio
Annalisa Chiappella
Ana Marin-Niebla
Rory McCulloch
Guido Gini
Tommasina Perrone
Luca Nassi
Elsa Pennese
Piero Maria Stefani
Maria Christina Cox
Valentina Bozzoli
Alberto Fabbri
Valentina Polli
Simone Ferrero
Maria Isabel Alvarez De Celis
Antonello Sica
Luca Petrucci
Luca Arcaini
Simon Rule
Mauro Krampera
Umberto Vitolo
Monica Balzarotti
Leukemia, 2021, 35 : 787 - 795
[38] Frontline Management Strategies for Younger, Fit Patients With Mantle Cell Lymphoma
Fowler, Nathan H.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2013, 11 (12) : 4 - 6
[39] Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
Andrea Borgerding
Justin Hasenkamp
Bertram Glaß
Gerald Wulf
Lorenz Trümper
Annals of Hematology, 2010, 89 : 283 - 289
[40] Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
Borgerding, Andrea
Hasenkamp, Justin
Glass, Bertram
Wulf, Gerald
Truemper, Lorenz
ANNALS OF HEMATOLOGY, 2010, 89 (03) : 283 - 289

← 1 2 3 4 5 →